Skip to main content

Type 2 diabetes and glycemic control

medwireNews

10-05-2023 | Type 2 diabetes | News

ONWARDS 5: Weekly insulin icodec with app shows real-world promise for type 2 diabetes

Result from ONWARDS 5 trial show weekly insulin icodec plus a dosing app offers greater reductions in glycated hemoglobin than daily basal insulin analogs for type 2 diabetes.

07-20-2023 | Type 2 diabetes | News

Triple agonist shows promise for both glycemic and weight control

Treating people with type 2 diabetes with the triple agonist retatrutide shows promising improvements in both glycemic control and reduction in obesity.

03-01-2023 | Flash glucose monitoring | News

One-off pre-consultation isCGM use helpful in type 2 diabetes

A short period of intermittently scanned continuous glucose monitoring prior to a first endocrinologist consultation can improve glycemic outcomes for people with type 2 diabetes, report the SPOT FIRST study researchers.

02-03-2023 | Empagliflozin | News

DINAMO: Empagliflozin shows promise for young people with type 2 diabetes

Empagliflozin, but not linagliptin, provides “clinically relevant” improvements in glycemic control versus placebo in children and adolescents with type 2 diabetes, report the DINAMO investigators.

01-16-2023 | Diet | News

Microbiome support improves type 2 diabetes outcomes

A randomised trial shows that use of a prebiotic fibre-enriched nutritional formula results in improved life quality and, potentially, better glycaemic control in people with type 2 diabetes.

12-13-2022 | Diet | News

Low-carb, high-fat diet gives glycemic benefits in randomized trial

Randomized trial findings show reduced glycated hemoglobin and bodyweight in people with type 2 diabetes following a calorie-unrestricted low-carbohydrate, high-fat diet versus a high-carbohydrate, low-fat approach.

Close up of doctor explaining treatment methods to patient

12-05-2022 | SGLT2 inhibitors | News

Algorithm could optimize SGLT2 vs DPP-4 inhibitor decisions in clinical practice

An algorithm based on real-world clinical data could support decisions between use of SGLT2 inhibitors and DPP-4 inhibitors in people with type 2 diabetes.

10-24-2022 | Cardiovascular outcomes | News

Meta-analysis may guide optimal type 2 diabetes glucose-lowering agent for MACE protection

Age, duration of type 2 diabetes, and race may help guide choice of glucose-lowering therapy for individuals with established CVD or those at high risk, say the authors of a systematic review and meta-analysis published in eClinicalMedicine.

09-23-2022 | EASD 2022 | Conference coverage | News

Degree of autoimmunity impacts CVD risk in LADA

Research suggests that people with latent autoimmune diabetes in adults and high levels of glutamic acid decarboxylase antibodies have a higher risk for cardiovascular disease than those with lower autoantibody levels.

09-22-2022 | EASD 2022 | Conference coverage | News

​​​​​​​Psychologic resilience tied to glycemic control after type 1 diabetes diagnosis

Researchers find psychologic resilience to be predictive of glycated hemoglobin levels in the 3 years after type 1 diabetes diagnosis.

08-23-2022 | Telehealth | News

Comprehensive telehealth success for poorly controlled type 2 diabetes

A randomized trial shows that comprehensive care resulting in improved glycemic control among people with persistently poorly controlled type 2 diabetes can be delivered via telehealth.

08-04-2022 | Tirzepatide | News

SURPASS J trials support tirzepatide use in Japanese people with type 2 diabetes

Tirzepatide is a promising treatment option for Japanese people with type 2 diabetes when used as monotherapy or added to antihyperglycemic agents, show the SURPASS J-mono and SURPASS J-combo trials.

Healthy breakfast - symbolic image with model

07-21-2022 | Sotagliflozin | News

Sotagliflozin effects differ from empagliflozin only at breakfast

The only notable short-term differences in the effects of sotagliflozin and empagliflozin occur in glucose metabolism after breakfast, show findings from a randomized trial.

Syringe and glucometer on a table - blood sugar in diabetes concept

06-14-2022 | Pathogenesis | News

People with ‘low BMI diabetes’ have a unique metabolic profile

Researchers have characterized an atypical form of diabetes in Indian men with low BMI, which has a unique metabolic profile setting it apart from type 1 and type 2 diabetes.

06-07-2022 | ADA 2022 | Conference coverage | News

​​​​​​​Artificial intelligence platform shows promise for type 2 diabetes remission

An artificial intelligence platform known as Whole Body Twin could be one answer to reversing type 2 diabetes, research suggests.

05-26-2022 | Insulin glargine | News

Real-world support for adding Gla-300 to GLP-1 receptor agonists in type 2 diabetes

The addition of insulin glargine 300 units/mL to glucagon-like peptide-1 receptor agonist therapy in people with type 2 diabetes results in improved glycemic control without increasing risk for hypoglycemia, suggest findings from the real-world DELIVER-G study.

Doctor vaccinating a senior woman

04-29-2022 | ATTD 2022 | Conference coverage | News

Poor glucose control risks SARS-CoV-2 infection despite immunization in type 2 diabetes

Poor glycemic control is associated with an impaired immune response to vaccination against SARS-CoV-2 and an increased risk for breakthrough infections in people with type 2 diabetes, report researchers.

Mixed diabetes medications

04-11-2022 | Medications | News

Therapeutic inertia increasing in type 2 diabetes

The proportion of individuals receiving second-line therapy for diabetes has decreased over time despite worsening glycemic control over the same period, US study findings indicate.

04-08-2022 | DUKPC 2022 | Conference coverage | News

Within-class switch to semaglutide brings benefits in real-world cohort

Real-world data confirm glycated hemoglobin and weight benefits, albeit attenuated, for people with type 2 diabetes switching to injectable semaglutide from other GLP-1 receptor agonists.

04-07-2022 | Mental health | News

Mental illness no barrier to glucose control in type 2 diabetes

People with type 2 diabetes who have mental health conditions are just as likely as those who do not to achieve their blood glucose targets, report researchers.